Status:
UNKNOWN
Circulating DNA in Surgically Treated NSCLC
Lead Sponsor:
Helsinki University Central Hospital
Collaborating Sponsors:
Institute for Molecular Medicine
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
20+ years
Brief Summary
* The investigators will prospectively recruit 100 NSCLC patients. The cfDNA samples will be gathered before the surgery and postoperatively 4-6 weeks after surgery and at 6 and 12 months follow-up vi...
Detailed Description
Plasma liquid biopsy is rapidly emerging non-invasive diagnostic tool that could be used as a surrogate for tumor biopsy or disease activity. Circulating cell-free DNA (cfDNA) is short fragment double...
Eligibility Criteria
Inclusion
- The inclusion criteria into this study is histologically confirmed NSCLC eligible for surgical treatment and naïve for systemic oncological treatments with either formalin-fixed paraffin-embedded tissue or fresh frozen tissue sample available.
Exclusion
- prior metastatic solid cancer, hematological malignancy, known hereditary cancer syndrome, and pregnancy
Key Trial Info
Start Date :
July 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04037150
Start Date
July 1 2019
End Date
December 31 2020
Last Update
August 6 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Helsinki University Central Hospital
Helsinki, Uusimaa, Finland, 00270